Braveheart Bio reports Q2 2026 financial results
Company announced $122.8M cash balance and advanced Phase 3 LIONHEART-HCM trial for cardiac drug BHB-1893.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day